Key Takeaways
- Newron Pharmaceuticals secures €38 million for the development of evenamide, targeting treatment-resistant schizophrenia.
- Evenamide’s mechanism focuses on modulating sodium channels rather than blocking dopamine receptors, aiming to improve a wider range of symptoms.
- The success of evenamide in Phase III trials could offer a new treatment option for patients unresponsive to standard therapies by late 2026.
Even amid increasing scrutiny of traditional schizophrenia therapies, Newron Pharmaceuticals has announced a €38 million funding agreement to advance its treatment candidate, evenamide. The deal consists of an upfront payment of €15 million, with additional funds contingent on development milestones and clinical trial outcomes. This investment aims to support operational needs as the company prepares for pivotal Phase III readouts expected in late 2026.
Many current schizophrenia treatments primarily target dopamine D2 receptors, which work for a segment of patients but leave many others without effective options. Treatment-resistant schizophrenia affects an estimated one-third of those diagnosed. Current medications, even clozapine, do not consistently manage symptoms, leading to questioning whether dopamine dysregulation is the primary issue. Researchers like neuroscientist Anthony Grace suggest the real problem may lie in the hippocampal circuits.
In contrast to traditional approaches, evenamide works by selectively modulating voltage-gated sodium channels to control abnormal neuronal hyperactivity, rather than blocking dopamine receptors. Newron argues that evenamide normalizes glutamate release while maintaining balance at baseline levels. Preclinical findings suggest that evenamide may enhance the effectiveness of existing antipsychotics, which raises hopes for broader symptom coverage encompassing positive, negative, and cognitive symptoms in schizophrenia.
While many therapies aim only to address hallucinations and delusions, evenamide’s potential to influence a broader spectrum of schizophrenia symptoms could represent a significant advancement. It may also avoid some side effects associated with dopamine antagonists.
Despite the promising approach, the field of schizophrenia treatment has seen setbacks with other non-dopaminergic therapies struggling in late-stage trials. However, there remains substantial interest in innovative treatments. Over 55 companies are working on different schizophrenia therapies, with an increasing focus on “circuit” medicines that modulate gluta-matergic pathways.
With preparations underway, Newron’s ENIGMA-TRS program includes a one-year, double-blind Phase III trial and a 12-week pivotal study that will evaluate evenamide as an add-on for patients continuing with traditional antipsychotics. If successful, evenamide could become the first specifically designated add-on therapy for treatment-resistant schizophrenia, marking a watershed moment in the landscape of schizophrenia management. Results from these trials, expected in late 2026, will ultimately determine the efficacy and potential market positioning of evenamide.
The content above is a summary. For more details, see the source article.